Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin
Number experiencing adverse effects · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).
1 finding from 1 review
- Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes onlyRR 1.47 [0.81, 2.66]1 study · 294 participantsModerate